Dechra Pharmaceuticals’ share price hits record peaks! Is it a top UK share to buy?

The Dechra Pharmaceuticals share price has just risen to new all-time highs. Here’s why I think it’s a good buy today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Dechra Pharmaceuticals (LSE: DPH) share price has been steadily improving in health during the past year. The business — which manufactures medicines for both companion animals and livestock — has risen 52% in value since early June 2020. This UK healthcare share hit fresh record peaks of £43.20 on Tuesday too, after it released fresh trading news.

Dechra’s share price settled lower and it closed Tuesday’s session at £42.52. Still, this represented a healthy 3% rise on the day. And I think the FTSE 250 company will continue to climb in value.

Sales tipped to beat estimates

In its latest sunny update, Dechra announced that trading for the full year to June 30 is likely to beat market expectations.

Should you invest £1,000 in National Grid right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if National Grid made the list?

See the 6 stocks

In February it advised that it had experienced a “strong performance” for the first seven months of financial 2021. And yesterday Dechra said it has “continued to benefit from strong market fundamentals as well as lower underlying selling, general and administration costs” following the Covid-19 outbreak.

Pre-Brexit stockpiles of its medicines are set to finish unwinding and coronavirus restrictions are on course to keep easing. So, Dechra “is increasingly confident that this strong performance will continue for the rest of this financial year.”

The UK share said full-year revenue is likely to exceed current consensus predictions, therefore. Trading is likely to be more evenly distributed than previously guided between the first and second halves of the financial year too.

Profits surge drives Dechra’s share price

Dechra Pharmaceuticals’ share price has exploded in recent years. A strong record of annual earnings growth has seen the FTSE 250 share rise 310% in value over the past half a decade. And City analysts are expecting profits at the business to continue rising at a swift pace.

The number crunchers reckon that earnings will rise 11% in the financial year to June 2021. And they’re forecasting a 7% bottom-line advance in fiscal 2022.

It’s worth bearing in mind that Dechra trades on an elevated forward price-to-earnings (P/E) ratio of 39 times. This increases the chances of a share price correction should news flow around the company begin to disappoint. This could include problems with medicines R&D, a not uncommon problem in the pharma industry that can result in large extra costs and lost revenues.

Why I’d buy this UK share

That being said, I still think Dechra is a good buy, even at today’s high price. This is because the veterinary medicines market is expected to keep on growing rapidly. Analysts at Grand View Research expect it to expand at a compound annual growth rate of 7.4% through to 2028. They reckon this will be driven by “rising R&D and procedural advancements, pet adoption rate, and increasing consumption of meats and mandatory vaccination.”

And I think Dechra, with its broad stable of products and healthy product pipeline, is well placed to exploit this booming industry.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What’s up with the Lloyds share price?

The Lloyds share price is up 26% in 2025, representing one of the strongest performance on the FTSE 100. Dr…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Here’s how a 40-year-old could start investing £100 per week to retire early

If a 40-year-old decides to start investing today, here's how they could potentially turn £100 a week into over £500k…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

The FTSE 100 is up 60% in 5 years. Here’s why — and a big lesson!

The flagship FTSE 100 index has put in a very strong performance over five years. There's a specific reason for…

Read more »

Investing Articles

How much do investors need in an ISA to earn a £2,500 monthly passive income?

Charlie Carman explores how investors could strive for £30k in tax-free passive income each year from a dividend stock portfolio.

Read more »

Investing Articles

How much would a 45-year-old need to invest in an ISA to earn a £1k monthly passive income at 65?

Harvey Jones looks at how much an investor would need to put away every month to build a steady passive…

Read more »

Investing Articles

3 things to do ahead of the new 2025-26 ISA year

It's time for us all to put on our investing boots and get to work on developing our plans for…

Read more »

Older couple walking in park
Investing Articles

Is £150,000 enough to generate £1,000 a month in passive income?

Stephen Wright takes a look at three UK stocks with dividend yields above 8% that passive income investors might be…

Read more »

Investing Articles

Aim to earn a £50k second income in retirement by investing just this much each month

Even with a small monthly investment, it’s possible to earn a £50k second income with a successful investment strategy and…

Read more »